Recurrent Primary Peritoneal Carcinoma Not Yet Recruiting Phase 1 Trials for Talazoparib (DB11760)

IndicationStatusPhase
DBCOND0031168 (Recurrent Primary Peritoneal Carcinoma)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03968406Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersTreatment